Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria

2000 ◽  
Vol 85 (2) ◽  
pp. 156-157 ◽  
Author(s):  
Riccardo Asero
2014 ◽  
Vol 10 (1) ◽  
pp. 24 ◽  
Author(s):  
Nipun de Silva ◽  
Hasitha Damayanthi ◽  
Anoja Rajapakse ◽  
Chaturaka Rodrigo ◽  
Senaka Rajapakse

Allergy ◽  
2001 ◽  
Vol 56 (5) ◽  
pp. 456-457 ◽  
Author(s):  
R. Asero ◽  
A. Tedeschi ◽  
M. Lorini

Author(s):  
Ivan I. Balabolkin

There is presented the modern concept of pathogenesis of urticaria in children and the participation of immunopathological responses in its development, the influence of physical factors, clinical and pathogenetic variants of acute and chronic urticaria, its diagnosis and treatment. The expediency of differentiated therapy, based on the severity of urticaria, features of its development and response to treatment, is shown. The effectiveness of the treatment of urticaria in children with antihistamines, leukotriene receptor antagonists and glucocorticosteroids was noted. Positive result of anti-IgE-therapy was noted in children with severe forms of urticaria, resistant to pharmacotherapy.


Author(s):  
Andrei Pașca ◽  
Eduard-Alexandru Bonci ◽  
Codruța Chiuzan ◽  
Nicoleta Monica Jiboc ◽  
Vlad Alexandru Gâta ◽  
...  

Abstract Background Capsular Contracture (CC) is the most common long-term complication of breast surgery with prosthesis. Leukotriene Receptor Antagonists (LRAs) have been tested as a potential treatment; however, mixed results have been observed. Objectives This study presents a meta-analysis to clarify the treatment and prophylactic capabilities of LRAs in the management of CC. Methods A systematic literature search in the most popular English databases was performed to identify relevant primary publications. We included all studies that evaluated the treatment and preventive capabilities of LRAs using the Baker scale assessment. Results Six eligible studies were included based on predefined inclusion and exclusion criteria, totalling 2276 breasts, out of which 775 did not receive LRAs and 1501 did. Final pooled results showed that LRAs could help manage CC with a Risk Difference (RD) of -0.38 with the corresponding 95% Confidence Interval (CI) between -0.69 and -0.08, showing statistical significance at a Z value of 2.48, p=0.01. Subgroup analysis based on the type of drug used showed that only montelukast yielded statistical significance (RD=-0.27, 95% CI between -0.51 and -0.03, Z=2.20, p=0.03). Zafirlukast did not seem to influence CC. Further subgroup analysis based on treatment timing showed that prophylaxis was ineffective and only treatment for ongoing CC yielded statistical significance. Conclusions The current meta-analysis proved that LRAs could be used in the management of CC. Only treatment for the ongoing CC showed statistical significance. Montelukast seemed to be more efficient with a safer profile for adverse effects, while zafirlukast yielded no statistical significance.


Sign in / Sign up

Export Citation Format

Share Document